{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T20:10:00Z","timestamp":1756325400696,"version":"3.44.0"},"reference-count":27,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,2]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Haemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening syndrome characterised by dysregulated immune activation, inflammation and multiorgan failure. In adults, HLH often arises secondary to an underlying trigger including infections, malignancies, autoimmune conditions, immunodeficiencies, chemotherapy or bone marrow transplantation. Diffuse large B-cell lymphoma (DLBCL) contributes to about 5\u201310% of malignancy-associated HLH. This case report highlights the clinical course of an elderly woman with HLH associated with DLBCL, who had an initial response in HLH with mini-R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone) therapy. However, on lymphoma progression, she presented with a severe form of HLH leading to her death. This clinical scenario needs further research with the development of interventions based on the enhanced knowledge of underlying physiology.<\/jats:p>","DOI":"10.1136\/bcr-2024-262378","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T15:39:26Z","timestamp":1734968366000},"page":"e262378","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Haemophagocytic lymphohistiocytosis (HLH) secondary to diffuse large B-cell lymphoma: uncommon complication of a common disease"],"prefix":"10.1136","volume":"17","author":[{"given":"Rahul","family":"Mishra","sequence":"first","affiliation":[{"name":"Internal Medicine, Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabia","family":"Javed","sequence":"additional","affiliation":[{"name":"Internal Medicine, Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nargiz","family":"Muganlinskaya","sequence":"additional","affiliation":[{"name":"Internal Medicine, Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, USA"},{"name":"Internal Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Meisenberg","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Luminis Health Anne Arundel Medical Center, Annapolis, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,12,22]]},"reference":[{"key":"2025082712294960000_17.12.e262378.1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21039"},{"key":"2025082712294960000_17.12.e262378.2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1210041","article-title":"Approaching hemophagocytic lymphohistiocytosis","volume":"14","author":"Chinnici","year":"2023","journal-title":"Front Immunol"},{"key":"2025082712294960000_17.12.e262378.3","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S46255"},{"key":"2025082712294960000_17.12.e262378.4","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.551153"},{"key":"2025082712294960000_17.12.e262378.5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjh.13837","article-title":"Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years","volume":"172","author":"Schram","year":"2016","journal-title":"Br J Haematol"},{"key":"2025082712294960000_17.12.e262378.6","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/cncr.30084","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes","volume":"122","author":"Tamamyan","year":"2016","journal-title":"Cancer"},{"key":"2025082712294960000_17.12.e262378.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.12.012"},{"key":"2025082712294960000_17.12.e262378.8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.14740\/jmc3521","article-title":"Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Clinical Case Series in a Predominantly Hispanic Cohort","volume":"11","author":"Desai","year":"2020","journal-title":"J Med Cases"},{"key":"2025082712294960000_17.12.e262378.9","first-page":"1163","article-title":"Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base","volume":"26","author":"Olszewski","year":"2015","journal-title":"Cancer Causes Control"},{"key":"2025082712294960000_17.12.e262378.10","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.07012"},{"key":"2025082712294960000_17.12.e262378.11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428190009060325","article-title":"B-cell lymphoma-associated hemophagocytic syndrome","volume":"38","author":"Shimazaki","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"2025082712294960000_17.12.e262378.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618"},{"key":"2025082712294960000_17.12.e262378.13","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21423"},{"key":"2025082712294960000_17.12.e262378.14","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025082712294960000_17.12.e262378.15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood.2021012764","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","journal-title":"Blood"},{"key":"2025082712294960000_17.12.e262378.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061839","article-title":"Diagnosis and Management of Adult Malignancy-Associated Hemophagocytic Lymphohistiocytosis","volume":"15","author":"Lee","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025082712294960000_17.12.e262378.17","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-185190","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance","volume":"142","author":"Ebinama","year":"2023","journal-title":"Blood"},{"key":"2025082712294960000_17.12.e262378.18","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025082712294960000_17.12.e262378.19","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(199705)28:5<342::AID-MPO3>3.0.CO;2-H"},{"key":"2025082712294960000_17.12.e262378.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb05095.x"},{"key":"2025082712294960000_17.12.e262378.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788349"},{"key":"2025082712294960000_17.12.e262378.22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30826"},{"key":"2025082712294960000_17.12.e262378.23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"2025082712294960000_17.12.e262378.24","unstructured":"Research C for DE . FDA approves emapalumab for hemophagocytic lymphohistiocytosis. FDA; 2019. Available: https:\/\/www.fda.gov\/drugs\/fda-approves-emapalumab-hemophagocytic-lymphohistiocytosis"},{"key":"2025082712294960000_17.12.e262378.25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001333"},{"key":"2025082712294960000_17.12.e262378.26","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02516-1","article-title":"Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study","volume":"17","author":"Kim","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2025082712294960000_17.12.e262378.27","doi-asserted-by":"crossref","DOI":"10.1007\/s12672-022-00476-3","article-title":"Hemophagocytic lymphohistiocytosis: a rare disease unveiling the diagnosis of EBV-related large B cell lymphoma in a patient with HIV","volume":"13","author":"Noveihed","year":"2022","journal-title":"Discov Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-262378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:29:58Z","timestamp":1756322998000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-262378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,22]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bcr-2024-262378"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-262378","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}